Merck Reports Mixed Q4/FY25 Results, Strong New Product Growth, and Lower 2026 EPS Guidance Due to $9.2B Cidara Acquisition

summarizeZusammenfassung

Merck's latest earnings report presents a mixed financial picture, with strong operational performance in key growth drivers like KEYTRUDA and new product launches (WINREVAIR, CAPVAXIVE) offset by a significant decline in GARDASIL sales. The full-year 2026 non-GAAP EPS guidance is notably lower than 2025, primarily due to a substantial one-time charge of approximately $3.65 per share related to the $9.2 billion acquisition of Cidara Therapeutics. While this charge impacts short-term profitability metrics, the acquisition strengthens Merck's pipeline with MK-1406, an investigational influenza antiviral. The company's continued pipeline advancements, including positive Phase 3 trial results and FDA priority review vouchers, underscore its long-term growth strategy. Investors will need to weigh the immediate impact of the acquisition charge against the strategic benefits of portfolio expansion and ongoing product strength, especially as the stock trades near its 52-week high.

check_boxSchlusselereignisse

• Q4 and Full-Year 2025 Financial Performance

  Fourth-quarter worldwide sales grew 5% to $16.4 billion, with non-GAAP EPS at $2.04 (up 19%). Full-year 2025 worldwide sales reached $65.0 billion (up 1%), and non-GAAP EPS was $8.98 (up 17%).

• 2026 Financial Outlook

  Merck anticipates full-year 2026 worldwide sales between $65.5 billion and $67.0 billion. Non-GAAP EPS is projected to be between $5.00 and $5.15, including a one-time charge of approximately $3.65 per share related to the Cidara acquisition.

• Key Product Dynamics

  KEYTRUDA/KEYTRUDA QLEX sales grew 7% to $31.7 billion for the full year 2025. New launches WINREVAIR and CAPVAXIVE showed strong uptake, with sales of $1.4 billion and $759 million respectively. GARDASIL/GARDASIL 9 sales declined 39% to $5.2 billion.

• Strategic Acquisitions and Pipeline Advancements

  The company completed the acquisition of Cidara Therapeutics for approximately $9.2 billion, adding MK-1406 to its portfolio. Merck also announced positive late-stage trial results from 18 Phase 3 trials in 2025 and received FDA priority review vouchers for sac-TMT and enlicitide decanoate.

auto_awesomeAnalyse

Merck's latest earnings report presents a mixed financial picture, with strong operational performance in key growth drivers like KEYTRUDA and new product launches (WINREVAIR, CAPVAXIVE) offset by a significant decline in GARDASIL sales. The full-year 2026 non-GAAP EPS guidance is notably lower than 2025, primarily due to a substantial one-time charge of approximately $3.65 per share related to the $9.2 billion acquisition of Cidara Therapeutics. While this charge impacts short-term profitability metrics, the acquisition strengthens Merck's pipeline with MK-1406, an investigational influenza antiviral. The company's continued pipeline advancements, including positive Phase 3 trial results and FDA priority review vouchers, underscore its long-term growth strategy. Investors will need to weigh the immediate impact of the acquisition charge against the strategic benefits of portfolio expansion and ongoing product strength, especially as the stock trades near its 52-week high.